Bradley G Hammill

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2581165/publications.pdf

Version: 2024-02-01

69 papers 3,305 citations

26 h-index

218677

56 g-index

70 all docs

70 docs citations

times ranked

70

4900 citing authors

#	Article	IF	CITATIONS
1	Evaluating fitness-for-use of electronic health records in pragmatic clinical trials: reported practices and recommendations. Journal of the American Medical Informatics Association: JAMIA, 2022, 29, 798-804.	4.4	7
2	Selection Bias in Observational Studies of Palliative Care: Lessons Learned. Journal of Pain and Symptom Management, 2021, 61, 1002-1011.e2.	1.2	4
3	Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. New England Journal of Medicine, 2021, 384, 1981-1990.	27.0	145
4	Regional Adiposity and Risk of Heart Failure and Mortality: The Jackson Heart Study. Journal of the American Heart Association, 2021, 10, e020920.	3.7	14
5	Early Increased Physical Activity, Cardiac Rehabilitation, and Survival After Implantable Cardioverter-Defibrillator Implantation. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007580.	2.2	6
6	Sacubitril/Valsartan Initiation and Postdischarge Adherence Among Patients Hospitalized for Heart Failure. Journal of Cardiac Failure, 2021, 27, 826-836.	1.7	30
7	Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. Journal of the American Heart Association, 2021, 10, e021459.	3.7	10
8	Life expectancy and voting patterns in the 2020 U.S. presidential election. SSM - Population Health, 2021, 15, 100840.	2.7	4
9	Validation of Cardiovascular End Points Ascertainment Leveraging Multisource Electronic Health Records Harmonized Into a Common Data Model in the ADAPTABLE Randomized Clinical Trial. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, CIRCOUTCOMES121008190.	2.2	9
10	Medicaid Coverage Disruptions Among Children Enrolled in North Carolina Medicaid From 2016 to 2018. JAMA Health Forum, 2021, 2, e214283.	2.2	3
11	Care continuity impacts medicare expenditures of older adults: Fact or fiction?. Healthcare, 2020, 8, 100364.	1.3	2
12	Data linkage in pharmacoepidemiology: A call for rigorous evaluation and reporting. Pharmacoepidemiology and Drug Safety, 2020, 29, 9-17.	1.9	34
13	Considerations for using distributed research networks to conduct aspects of randomized trials. Contemporary Clinical Trials Communications, 2020, 17, 100515.	1.1	5
14	Relationship Between HCAHPS Scores and Survey Response Rate Is Linked to Hospital Size. Journal of Patient Experience, 2020, 7, 1543-1548.	0.9	5
15	Computable Phenotype Implementation for a National, Multicenter Pragmatic Clinical Trial. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006292.	2.2	19
16	Outcomes and cost among Medicare beneficiaries hospitalized for heart failure assigned to accountable care organizations. American Heart Journal, 2020, 226, 13-23.	2.7	7
17	Rationale and Design of the Aspirin Dosing—A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial. JAMA Cardiology, 2020, 5, 598.	6.1	59
18	Association of Implantable Device Measured Physical Activity With Hospitalization for HeartÂFailure. JACC: Heart Failure, 2020, 8, 280-288.	4.1	15

#	Article	IF	CITATIONS
19	Trends in Treatment for Patients Hospitalized with Heart Failure with Preserved Ejection Fraction Before and After Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT). American Journal of Cardiology, 2020, 125, 1655-1660.	1.6	7
20	Characteristics of Acute Heart Failure Hospitalizations Based on Presenting Severity. Circulation: Heart Failure, 2019, 12, e005171.	3.9	15
21	Use and 1-year outcomes with conventional and drug-coated balloon angioplasty in patients with lower extremity peripheral artery disease. American Heart Journal, 2019, 217, 42-51.	2.7	16
22	The Burden of Congestion in Patients Hospitalized With Acute Decompensated Heart Failure. American Journal of Cardiology, 2019, 124, 545-553.	1.6	29
23	Use of Medicare Claims to Identify Adverse Clinical Outcomes After Mitral Valve Repair. Circulation: Cardiovascular Interventions, 2019, 12, e007451.	3.9	15
24	Measuring the burden of multimorbidity among Medicare beneficiaries via condition counts and cumulative duration. Health Services Research, 2019, 54, 484-491.	2.0	23
25	Hospital Resource Utilization BeforeÂandÂAfter TranscatheterÂAorticÂValve Replacement. Journal of the American College of Cardiology, 2019, 73, 1135-1146.	2.8	26
26	Early impact of guideline publication on angiotensin-receptor neprilysin inhibitor use among patients hospitalized for heart failure. American Heart Journal, 2018, 200, 134-140.	2.7	8
27	Hospital and clinical care costs associated with atrial fibrillation for Medicare beneficiaries in the Cardiovascular Health Study and the Framingham Heart Study. SAGE Open Medicine, 2018, 6, 205031211875944.	1.8	35
28	Linking a Total Ankle Arthroplasty Registry to Medicare Inpatient Claims without Unique Identifiers. Journal of Bone and Joint Surgery - Series A, 2018, 100, 1016-1022.	3.0	0
29	Disproportionate Use of Inpatient Care by Older Adults With Kidney Stones. Urology, 2018, 120, 103-108.	1.0	4
30	Prescriber continuity and medication availability in older adults with cardiometabolic conditions. SAGE Open Medicine, 2018, 6, 205031211875738.	1.8	6
31	Home-Time After Discharge Among Patients Hospitalized With Heart Failure. Journal of the American College of Cardiology, 2018, 71, 2643-2652.	2.8	72
32	Characterization of Mineralocorticoid Receptor Antagonist Therapy Initiation in High-Risk Patients With Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	18
33	Cardiovascular events and hospital resource utilization pre– and post–transcatheter mitral valve repair in high–surgical risk patients. American Heart Journal, 2017, 189, 146-157.	2.7	15
34	Prescriber Continuity and Disease Control of Older Adults. Medical Care, 2017, 55, 405-410.	2.4	23
35	Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction. JACC: Heart Failure, 2017, 5, 305-309.	4.1	101
36	Association of Practice-Level Hospital Use With End-of-Life Outcomes, Readmission, and Weekend Hospitalization Among Medicare Beneficiaries With Cancer. Journal of Oncology Practice, 2016, 12, e933-e943.	2.5	4

#	Article	IF	Citations
37	Few Disparities in Baseline Laboratory Testing After the Diuretic or Digoxin Initiation by Medicare Fee-For-Service Beneficiaries. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 714-722.	2.2	1
38	Use of the landmark method to address immortal person-time bias in comparative effectiveness research: a simulation study. Statistics in Medicine, 2016, 35, 4824-4836.	1.6	73
39	Frequency of Disparities in Laboratory Testing After Statin Initiation in Subjects ≥65ÂYears. American Journal of Cardiology, 2016, 118, 376-382.	1.6	1
40	Antihyperglycemic Medication Use Among Medicare Beneficiaries With Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease. Circulation: Heart Failure, 2016, 9, .	3.9	19
41	Significant Morbidity and Mortality Among Hospitalized End-Stage Liver Disease Patients in Medicare. Journal of Pain and Symptom Management, 2016, 52, 412-419.e1.	1.2	25
42	Longâ€Term Outcomes Among Elderly Survivors of Outâ€ofâ€Hospital Cardiac Arrest. Journal of the American Heart Association, 2016, 5, e002924.	3.7	31
43	Appropriate baseline laboratory testing following ACEI or ARB initiation by Medicare FFS beneficiaries. Pharmacoepidemiology and Drug Safety, 2016, 25, 1015-1022.	1.9	2
44	Use of Heart Failure Medical Therapies Among Patients With Left Ventricular Assist Devices: Insights From INTERMACS. Journal of Cardiac Failure, 2016, 22, 672-679.	1.7	34
45	Discharge heart rate and \hat{l}^2 -blocker dose in patients hospitalized with heart failure: Findings from the OPTIMIZE-HF registry. American Heart Journal, 2016, 173, 172-178.	2.7	28
46	Differences in health care use and outcomes by the timing of in-hospital worsening heart failure. American Heart Journal, 2015, 170, 1124-1132.	2.7	8
47	Linkage of Laboratory Results to Medicare Fee-for-Service Claims. Medical Care, 2015, 53, 974-979.	2.4	15
48	Effectiveness of implantable cardioverter-defibrillators in survivors of inhospital cardiac arrest. American Heart Journal, 2015, 169, 870-878.e1.	2.7	3
49	Consistency of Laboratory Monitoring During Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients With Heart Failure. JAMA - Journal of the American Medical Association, 2015, 314, 1973.	7.4	53
50	Inâ∈Hospital Worsening Heart Failure and Associations With Mortality, Readmission, and Healthcare Utilization. Journal of the American Heart Association, 2014, 3, .	3.7	48
51	Clinical Effectiveness of Cardiac Resynchronization Therapy Versus Medical Therapy Alone Among Patients With Heart Failure. Circulation: Heart Failure, 2014, 7, 926-934.	3.9	20
52	Association Between Prophylactic Implantable Cardioverter-Defibrillators and Survival in Patients With Left Ventricular Ejection Fraction Between 30% and 35%. JAMA - Journal of the American Medical Association, 2014, 311, 2209.	7.4	35
53	Adherence and Persistence in the Use of Warfarin After Hospital Discharge Among Patients With Heart Failure and Atrial Fibrillation. Journal of Cardiac Failure, 2014, 20, 23-30.	1.7	20
54	Survival After Primary Prevention Implantable Cardioverter-Defibrillator Placement Among Patients With Chronic Kidney Disease. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 793-799.	4.8	45

#	Article	IF	CITATIONS
55	Associations Between Anticoagulation Therapy and Risks of Mortality and Readmission Among Patients With Heart Failure and Atrial Fibrillation. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 670-679.	2.2	5
56	Trends in the Use and Outcomes of Ventricular AssistÂDevices Among MedicareÂBeneficiaries, 2006ÂThrough 2011. Journal of the American College of Cardiology, 2014, 63, 1395-1404.	2.8	56
57	Cost Analysis of Periprocedural Imaging in Patients Undergoing Catheter Ablation for Atrial Fibrillation. American Journal of Cardiology, 2014, 114, 266-271.	1.6	5
58	Outcomes of Medicare Beneficiaries With Heart Failure and Atrial Fibrillation. JACC: Heart Failure, 2014, 2, 41-48.	4.1	52
59	Anti-VEGF Treatment Patterns for Neovascular Age-Related Macular Degeneration Among Medicare Beneficiaries. American Journal of Ophthalmology, 2014, 158, 537-543.e2.	3.3	55
60	Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure. American Heart Journal, 2013, 165, 979-986.e1.	2.7	74
61	Associations Between Use of the Hospitalist Model and Quality of Care and Outcomes of Older Patients Hospitalized for Heart Failure. JACC: Heart Failure, 2013, 1, 445-453.	4.1	30
62	COSTS OF NEWLY DIAGNOSED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AMONG MEDICARE BENEFICIARIES, 2004–2008. Retina, 2013, 33, 854-861.	1.7	11
63	Incidence and Prevalence of Atrial Fibrillation and Associated Mortality Among Medicare Beneficiaries: 1993–2007. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 85-93.	2.2	476
64	Outcomes of Medicare Beneficiaries Undergoing Catheter Ablation for Atrial Fibrillation. Circulation, 2012, 126, 2200-2207.	1.6	138
65	Performance of propensity score methods when comparison groups originate from different data sources. Pharmacoepidemiology and Drug Safety, 2012, 21, 81-89.	1.9	4
66	Incremental Value of Clinical Data Beyond Claims Data in Predicting 30-Day Outcomes After Heart Failure Hospitalization. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 60-67.	2.2	96
67	Relationship Between Cardiac Rehabilitation and Long-Term Risks of Death and Myocardial Infarction Among Elderly Medicare Beneficiaries. Circulation, 2010, 121, 63-70.	1.6	438
68	Linking inpatient clinical registry data to Medicare claims data using indirect identifiers. American Heart Journal, 2009, 157, 995-1000.	2.7	344
69	Impact of Heart Failure on Patients Undergoing Major Noncardiac Surgery. Anesthesiology, 2008, 108, 559-567.	2.5	265